Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.35 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.35 |
| ▸ | SLC6A1 | P30531 | 4/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.35 |
| ▸ | SLC6A11 | P48066 | 3/20 | 0.35 |
| ▸ | SLC6A13 | Q9NSD5 | 3/20 | 0.35 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.35 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.35 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.35 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.35 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | PRCP | P42785 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL5772837 | 1.00 | CHRNB2 (0.35) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| Trifluoroacetic Acid SCHEMBL1771251 | 0.90 | SLC6A1 (0.42) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| Trifluoroacetic Acid SCHEMBL2912962 | 0.89 | GABRP (0.39) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| Trifluoroacetic Acid SCHEMBL932729 | 0.85 | CHRNB2 (0.34) | CHRNB2CHRNA3CHRNA4PKM | |
| Trifluoroacetic Acid SCHEMBL20576082 | 0.83 | SLC6A1 (0.33) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| Trifluoroacetic Acid SCHEMBL3338487 | 0.81 | SLC6A4 (0.33) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| Trifluoroacetic Acid SCHEMBL21063469 | 0.81 | SLC6A1 (0.40) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| Trifluoroacetic Acid SCHEMBL3338497 | 0.81 | SLC6A4 (0.33) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL492237 | 0.80 | — | — | |
| SCHEMBL321509 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250313560-A1 | Novel bicyclic benzylamido pyridine derivatives as SOS1 inhibitors | BOEHRINGER INGELHEIM INT (DE) | 2025-10-09 | — | — | US | disclosed |
| EP-3307741-B1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARIC M2 RECEPTOR | Bayer Pharma AG (DE) | 2020-10-28 | — | — | EP | disclosed |
| EP-3692991-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC M2 RECEPTOR | Bayer Pharma Aktiengesellschaft (DE) | 2020-08-12 | — | — | EP | disclosed |
| US-10435403-B2 | Positive allosteric modulators of muscarinic M2 receptor | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-10-08 | — | — | US | disclosed |
| US-20180297994-A1 | POSITIVE ALLOSTERIC MODULATORS OF MUSCARINIC M2 RECEPTOR | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-10-18 | — | — | US | disclosed |
| EP-3307741-A1 | POSITIVE ALLOSTERIC MODULATORS OF MUSCARINIC M2 RECEPTOR | Bayer Pharma Aktiengesellschaft (DE) | 2018-04-18 | — | — | EP | disclosed |
| WO-2016198342-A1 | POSITIVE ALLOSTERIC MODULATORS OF MUSCARINIC M2 RECEPTOR | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-12-15 | — | — | WO | disclosed |
| EP-1620437-B1 | 5,7-DIAMINOPYRAZOLO¬4,3-D PYRIMIDINES USEFUL IN THE TRAETMENT OF HYPERTENSION | PFIZER LTD (GB) | 2009-06-17 | — | — | EP | disclosed |
| US-20070270412-A1 | NOVEL PHARMACEUTICALS | PFIZER INC | 2007-11-22 | — | — | US | disclosed |
| US-7262192-B2 | Substituted pyrazolo[4,3-d]pyrimidines and their use as PDE-5 inhibitors | PFIZER INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-7060836-B2 | Lactams as tachykinin antagonists | PFIZER, INC (US) | 2006-06-13 | — | — | US | disclosed |
| CN-1780841-A | 5,7-diaminopyrazolo[4,3-d]pyrimidines useful in the traetment of hypertension | PFIZER LTD (GB) | 2006-05-31 | — | — | CN | disclosed |
| US-20050043325-A1 | Novel pharmaceuticals | PFIZER INC | 2005-02-24 | — | — | US | disclosed |
| EP-1456200-A1 | LACTAMS AS TACHYKININ ANTAGONISTS | Pfizer Limited (GB) | 2004-09-15 | — | — | EP | disclosed |
| US-20040132710-A1 | Lactams as tachkinin antagonists | PFIZER INC. | 2004-07-08 | — | — | US | disclosed |
| WO-2003051868-A1 | LACTAMS AS TACHYKININ ANTAGONISTS | PFIZER LIMITED (GB) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180297994-A1 | POSITIVE ALLOSTERIC MODULATORS OF MUSCARINIC M2 RECEPTOR | CHRM2, CHRM1, CHRM3 | CHRNB2 27/4885CHRNA3 12/4885CHRNA4 15/4885 |
| US-20050043325-A1 | Novel pharmaceuticals | ABCB11, PCSK9, SLC10A1 | CHRNB2 3662/4885CHRNA3 3999/4885CHRNA4 4096/4885 |
| US-20040132710-A1 | Lactams as tachkinin antagonists | PROKR1, TACR2, TACR1 | CHRNB2 1211/4885CHRNA3 1726/4885CHRNA4 2210/4885 |
| US-10435403-B2 | Positive allosteric modulators of muscarinic M2 receptor | CHRM2, CHRM1, CHRM3 | CHRNB2 27/4885CHRNA3 12/4885CHRNA4 15/4885 |
| US-20250313560-A1 | Novel bicyclic benzylamido pyridine derivatives as SOS1 inhibitors | SOS1, SOS2, RSU1 | CHRNB2 3635/4885CHRNA3 3701/4885CHRNA4 4163/4885 |
| US-20070270412-A1 | NOVEL PHARMACEUTICALS | ABCB11, PCSK9, SLC10A1 | CHRNB2 3662/4885CHRNA3 3999/4885CHRNA4 4096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.